Abstract
Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Current Pharmaceutical Biotechnology
Title: Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Volume: 1 Issue: 1
Author(s): Ignacio Perez-Roger, Carmen Ivorra, Antonio Diez, Maria Jose Cortes, Enric Poch, Silvia M. Sanz-Gonzalez and Vicente Andres
Affiliation:
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Abstract: Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Export Options
About this article
Cite this article as:
Perez-Roger Ignacio, Ivorra Carmen, Diez Antonio, Cortes Jose Maria, Poch Enric, Sanz-Gonzalez M. Silvia and Andres Vicente, Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201010001010107
DOI https://dx.doi.org/10.2174/1389201010001010107 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia
Protein & Peptide Letters Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Pathobiology of Head and Neck Squamous Tumorigenesis
Current Cancer Drug Targets Subject Index To Volume 7
Current Drug Targets Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Recent Advances in Two-Photon Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Current Drug Discovery Technologies Benzofuran-Based Estrogen Receptor α Modulators as Anti-Cancer Therapeutics: In Silico and Experimental Studies
Current Medicinal Chemistry Vitamin D Receptor Signaling of Monocytic Differentiation in Human Leukemia Cells: Role of MAPK Pathways in Transcription Factor Activation
Current Topics in Medicinal Chemistry microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry